

Note: Questions for the Diplomate in Safety Pharmacology (DSP) exam were prepared by a committee composed of 16 experts from various fields of safety pharmacology and from diverse backgrounds (academic, industry and regulatory agency). At least 2 years of relevant work experience in the field of safety pharmacology is required for eligibility to the DSP certification. While a review of the scientific literature is an important aspect of preparation for the DSP certification, the knowledge and skills gained through experience while practicing the discipline are considered an essential element to succeed.

This list of references below was prepared to help candidates during preparation for the DSP examination and should be used as a general guidance only. Questions for the DSP examination were not specifically derived from the articles included in the list below. Not all publications included in the list below are covered by specific questions at the DSP examination. The correct answers for questions in the examination are not included in the articles from this suggested list. References not included in the list below may also constitute valuable study material.

Suggested Study Materials include:

DSP Webinar series: Focused Reviews in Safety Pharmacology (Part 1, 2, 3)
Download slides on our [Webinars page](#).

All **scientific articles** related to the scope of the examination presented above are published in the following journals:

- *Journal of Pharmacological & Toxicological Methods*
- *Regulatory Toxicology and Pharmacology*
- *British Journal of Pharmacology*
- *Journal of Cardiovascular Pharmacology*
- *Journal of Applied Toxicology*
- *Cardiovascular Toxicology*
- *Expert Opinion on Drug Safety*
- *Toxicology and Applied Pharmacology*
- *Fundamental and Clinical Pharmacology*

Books

- *Guyton and Hall textbook of Medical Physiology, 13th Edition, John E. Hall, PhD, 2016*
- *Principles of Safety Pharmacology (Handbook of Experimental Pharmacology), Michael K. Pugsley and Michael Curtis, Editors, 2015*
- *Nonclinical Assessment of Abuse Potential for New Pharmaceuticals, Carrie Markgraf, Thomas Hudzik & David Compton, Editors, 2015*
- *Electrocardiography of Laboratory Animals, Jeffrey W. Richig & Meg M. Sleeper, 2013*
- *Textbook of Veterinary Internal Medicine, Stephen Ettinger and Edward C. Feldman, 7th Edition (earlier editions may not have the same chapters)*
 - Chapters on Electrocardiographic Techniques, Echocardiography, Syncope, Pathophysiology of Heart Failure, Electrocardiography and Cardiac Arrhythmias, Neurologic Examination and Neuroanatomic Diagnosis, Vestibular Disease, and Clinical Approach and Laboratory Evaluation of Renal Disease

Scientific Reference articles (sorted by category):

Regulatory guidelines

- Anon. (2000). ICHS7A: Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00. London. www.emea.eu.int/pdfs/human/ich/053900en.pdf
- Anon. (2005). HHS. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist. 70(202):61133-4. <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129122.pdf>
- Anon. (1997). Committee for Proprietary Medicinal Products (CPMP) Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. www.ganimed.biz/bibliothek/media/EMEA_CPMP_Dec1997.pdf
- Anon. (2005). Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14). <http://www.fda.gov/cber/gdlns/iche14qtc.pdf>
- Anon. (2010). Guidance for Industry Assessment of Abuse Potential of Drugs. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf>
- Anon. (2011). ICH S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. CPMP/ICH/302/95. (Revised version (R1) finalised June 2011.). <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf>
- Anon. (2009). ICH M3(R2): Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2_Guideline.pdf
- Anon. (2005). ICH S5(R2): Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2_Guideline.pdf
- Anon. (2006). Food and Drug Administration. Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf
- Anon. (2008). Committee for Human Medicinal Products (CHMP). Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications. EMEA/CHMP/SWP/169215/2005. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003305.pdf
- Anon. (2008). OECD: Guidance document on mammalian reproductive toxicity testing and assessment. ENV/JM/MONO(2008)16. [www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono\(2008\)16&doclanguage=en](http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2008)16&doclanguage=en)

Anon. (2008). Food and Drug Administration. Guidance for industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf

Anon. (2006). FDA Guidance for Industry, Investigators and Reviewers: Exploratory IND Studies. [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=exploratory IND&utm_content=1](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=exploratory%20IND&utm_content=1)

Anon. (2009). Nonclinical evaluation for anticancer pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf

Anon. (1995). Guidance for Industry Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (1995). <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074937.pdf>

Safety-related attrition/ strategies to address this (etc.)

Andersen, M. E., and Krewski, D. (2010). The vision of toxicity testing in the 21st century: Moving from discussion to action. *Toxicological Sciences* **117**:17-24.

Anon. (2004). Challenge and opportunity on the critical path to new medical products. Food and Drug Administration. <http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html>

Easter, A., Bell, M. E., Damewood, J. R., Redfern, W. S., Valentin, J. P., Winter, M. J., Fonck, C., and Bialecki, R. A. (2009). Approaches to seizure risk assessment in preclinical drug discovery. *Drug Discovery Today* **14**: 876-884.

Meta M, Litwak M, Arezzo J (2015) Assessment of seizure risk in pre-clinical studies: Strengths and limitations of the electroencephalogram (EEG). *Journal of Pharmacological and Toxicological Methods* **75**: 135–142.

Kola, I., and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? *Nature Reviews: Drug Discovery* **3**:711-715.

Kramer, J. A., Sgartz, J. E., and Morris, D. L. (2007). The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. *Nature Reviews: Drug Discovery* **6**:636-649.

Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., Pirmohamed, M., Pollard, C., Radford, J., Roome, N., Sager, P., Singh, S., Suter, T., Suter, W., Trafford, A., Volders, P., Wallis, R., Weaver, R., York, M., and Valentin, J. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? *Br. J. Pharmacol.* **163**:675-693.

Laverty, H., Benson, C., Cartwright, E., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? *Br. J. Pharmacol.* **163**:675-693.

Stevens, J. L., and Baker, T. K. (2009). The future of drug safety testing: expanding the view and narrowing the focus. *Drug Discovery Today.* **14**:162-167.

Specific clinical safety issues of interest to safety pharmacology

- Anon. (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *The Lancet* **360**:1903-1913.
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J. C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., and Brewer, B. for the ILLUMINATE Investigators. (2007). Effects of torcetrapib in patients at high risk for coronary events. *New England Journal of Medicine*. **357**:2109-2122.
- Cheng, H., and Force, T. (2010). Molecular mechanisms of cardiovascular toxicity of targeted cancer Therapeutics *Circulation Research*. **106**:21-34.
- Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez-Sendon, J. L., Steg, P. G., Tardif, J. C., Tavazzi, L., and Tendera, M. for the Heart Rate Working Group. (2007). Resting heart rate in cardiovascular disease. *Journal of the American College of Cardiology*. **50**:823-830.
- Kaul, S., and Diamond, G. A. (2010). Diabetes: Breaking news! Rosiglitazone and cardiovascular risk. *Nature Reviews Cardiology*. **7**:670-672.
- Mehta, S., Chen, H., Johnson, M., Aparasu, R. R. (2011). Risk of serious cardiac events in older adults using antipsychotic agents. *American Journal of Geriatric Pharmacotherapy*. **9**:120-132.
- Mellor, H. R., Bell, A. R., Valentin, J. P., Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. *Toxicological Sciences*. **120**: 14-32.
- Redfern, W. S., Waldron, G., Winter, M. J., Butler, P., Holbrook, M., Wallis, R., and Valentin, J. P. (2008). Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring? *J. Pharmacol. Toxicol. Methods*. **58**:110-117.
- Santosh, P. J., Sattar, S., and Canagaratnam, M. (2011). Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. *CNS Drugs*. **25**:737-763.
- Scheen, A. J. (2010). Cardiovascular risk-benefit profile of sibutramine. *American Journal of Cardiovascular Drugs*. **10**: 321-334.
- Scheiman, J. M., Hindley, C. E. (2010). Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. *Clinical Therapeutics*. **32**:667-677.
- Zuppinger, C., and Suter, T.M. (2010). Cancer therapy-associated cardiotoxicity and signaling in the myocardium. *J Cardiovasc Pharmacol*. **56**:141-146.

Preclinical to clinical translation

- Bass, A. S., Darpo, B., Breidenbach, A., et al. (2008). International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. *Br. J. Pharmacol*. **154**(7):1491-501.
- De Bruin, M. L., Pettersson, M., Meyboom, R. H. B., Hoes, A. W., and Leufkens, H. G. M. (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. *European Heart Journal*. **26**: 590-597.

Hamlin, R. L., and Altschuld, R. A. (2011). Extrapolation from mouse to man. *Circ. Cardiovasc. Imaging*. **4**(1):2-4.

Lemmer, B. (2006). The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man. *Pharmacol. Ther.* **111**(3):629-651.

Piccini, J. P., Whellan, D. J., Berridge, B. R., Finkle, J. K., Pettit, S. D., Stockbridge, N, Valentin, J. P., Vargas, H. M., and Krucoff, M. W. (2009). Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path. Initiative. *American Heart Journal*. **158**:317-326.

Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K. S., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J., and Hammond, T. G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. *Cardiovasc. Res.* **58**:32-45.

Trepakova, E. S., Koerner, J., Pettit, S. D., Valentin, J. P., and Committee, H. P. A. (2009). A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. *J. Pharmacol. Toxicol. Methods*. **60**:45-50. 1308.

Valentin, J. P., Bialecki, R., Ewart, L., Hammond, T., Leishmann, D., Lindgren, S., Martinez, V., Pollard, C., Redfern, W., and Wallis, R. (2009). A framework to assess the translation of safety pharmacology data to humans. *J. Pharmacol. Toxicol. Methods*. **60**:152-158. 1317.

Wallis, R. M. (2010). Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. *Br. J. Pharmacol.* **159**:115-121.

Bioinformatics/in silico/in vitro/ex vivo

Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., et al. (2012). Dynamic monitoring of beating periodicity of stem cell derived cardiomyocytes as a predictive tool for preclinical safety assessment. *Br. J. Pharmacol.* **165**(5):1424-1441.

Baker M. 2016. Statisticians issue warning on P values. *Nature* 531: 151.

Bowes J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., and Whitebread, S. (2012). Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. *Nature Reviews Drug Discovery*. **11**:909-922.

Jonsson, M. K. B., Wang, Q. D., and Becker, B. (2011). Impedance based detection of beating rhythm and proarrhythmic effects of compounds on stem cell derived cardiomyocytes. *Assay and drug development technologies*. **9**(6):589-599.

Lawrence, C. L., Bridgland-Taylor, M. H., Pollard, C. E., Hammond, T. G., Valentin, J. P. (2006). A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. *Br. J. Pharmacol.* **149**:845-860.

Lightbown, I. D., Johnson, M., Davis, A., Leaney, J., and Leishman, D. J. (2007). Towards automation of a valuable preclinical cardiac safety pharmacology assay: Evaluation of the effects of cardiac ion channel blockers on cardiac repolarisation in vitro. *J. Pharmacol. Toxicol. Methods*. **56**(2):194-202.

- Muster, W., Breidenbach, A., Fischer, H., Kirchner, S., Müller, L., and Pähler, A. (2008). Computational toxicology in drug development. *Drug Discovery Today*. **13**:303-310.
- Parkinson, J., Muthas, D., Clark, M., Boyer, S., Valentin, J. P., and Ewart, L. (2012). Application of data mining and visualization techniques for the prediction of drug-induced nausea in man. *Toxicological Sciences*. **126**: 275-284.
- Peng, S., Lacerca, A. E., Kirsch, G. E., Brown, A. M., and Bruening-Wright, A. (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. *J. Pharmacol. Toxicol. Methods*. **61**(3):277-286.
- Thomas, C. E., and Will, Y. (2012). The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. *Expert Opinion on Drug Discovery*. **7**:109-122.
- Valentin, J. P., Hoffmann, P., De Clerck, F., Hammond, T. G., and Hondeghem, L. (2004). Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. *J. Pharmacol. Toxicol. Methods*. **49**: 171-181.
- Williams, D. P., Shipley, R., Ellis, M. J., Webb, S., Ward, J., Gardner, I., and Creton, S. (2012). Novel in vitro and mathematical models for the prediction of chemical toxicity. *Toxicology Research* doi: 10.1039/c2tx20031g.

hERG/QT etc.

- Brimecombe, J. C., Kirsch, G. E., and Brown, A. M. (2009). Test article concentrations in the hERG assay: losses through perfusion, solubility and stability *J. Pharmacol. Toxicol. Methods*. **59**(1):29-34.
- Brown, A. M. (2004). Drugs, hERG and sudden death. *Cell Calcium*. **35**(6):543-547.
- Brown, A. M., and Rampe, D. (2000). Drug-Induced Long QT Syndrome: Is HERG the Root of All Evil. *Pharmaceutical News*. **7**(4):15-20.
- Brown, A. M. (2005). HERG block, QT liability and sudden cardiac death. *Novartis Found Symp*. **266**:118-31; discussion 131-5, 155-158.
- Brown, A. M. (2009). High throughput functional screening of an ion channel library for drug safety and efficacy. *Eur. Biophys. J*. **38**(3):273-278.
- Cavero, I. (2011). 10th annual meeting of the Safety Pharmacology Society: An overview. *Expert Opin. Drug Saf*. **10**(2):319-333.
- Cavero, I. (2012). Annual Meeting of the Safety Pharmacology Society: An overview. *Expert Opin. Drug Saf*. **11**(2):341-353.
- Cavero, I. (2013). Annual Meeting of the Safety Pharmacology Society: Spotlight on targeted oncology medicines. *Expert Opin. Drug Saf*. **12**(4):589-603.
- Chiang, A. Y., Holdsworth, D. L., and Leishman, D. J. (2006). A one-step approach to the analysis of the QT interval in conscious telemetrized dogs. *J. Pharmacol. Toxicol. Methods*. **54**(2):183-188.
- Chiang, A. Y., Mallinckrodt, C. H., Dmitrienko, A. A., and Leishman, D. J. (2010). Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation. *J. Pharmacol. Toxicol. Methods*. **62**(2):143-147.

- Davis, A. S. (1998). The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. *Hum. Exp. Toxicol.* **17**(12):677–680.
- Davis, A. S. (1998). The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods. *Clin. Cardiol.* **22**:513-518.
- Ficker, E., Dennis, A., Kuryshev, Y., Wible, B. A., and Brown, A. M. (2005). HERG channel trafficking. *Novartis Found Symp.* **266**:57-69; discussion 70-4, 95-9.
- Ficker, E., Jarolimek, W., Kiehn, J., Baumann, A., and Brown, A. M. (1998). Molecular determinants of dofetilide block of HERG K⁺ channels. *Circ. Res.* **82**(3):386-395.
- Ficker, E., Kuryshev, Y. A., Dennis, A. T., Obejero-Paz, C. A., Wang, L., Wible, B. A., and Brown, A. M. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. *Mol. Pharmacol.* **66**:33-44.
- Ficker, E., Obejero-Paz, C. A., Zhao, S., and Brown, A. M. (2002). The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (hERG) mutations. *J. Biol. Chem.* **277**:4989-4998.
- Fossa, A. A., and Zhou, M. (2010). Assessing QT prolongation and electrocardiography restitution using a beat-to-beat method. *Cardiol. J.* **17**(3):230-243.
- Garnett, C. E., Zhu, H., Malik, M., Fossa, A. A., Zhang, J., Badilini, F., Li, J., Darpö, B., Sager, P., and Rodriguez, I. (2012). Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. *Am. Heart. J.* **163**(6):912-930.
- Gralinski, M. R. (2003). The dog's role in the preclinical assessment of QT interval prolongation. *Toxicol. Pathol.* **31**(Suppl):11-16.
- Guth, B. D., Bass, A. S., Briscoe, R., Chivers, S., Markert, M., Siegl, P. K., and Valentin, J. P. (2009). Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. *J. Pharmacol. Toxicol. Methods.* **60**:107-116.
- Guth, B. D., and Rast, G. (2010). Dealing with hERG liabilities early: diverse approaches to an important goal in drug development. *Br. J. Pharmacol.* **159**:22-24.
- Hanson, L. A., Bass, A. S., Gintant, G., Mittelstadt, S., Rampe, D., and Thomas, K. (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. *J. Pharmacol. Toxicol. Methods.* **54**(2):116-129.
- Ishida, S., et al. (1997). Circadian variation of QT interval dispersion: Correlation with heart rate variability. *J. Electrocardiol.* **30**(3): 205-210.
- Jonker, D. M., Kenna, L. A., Leishman, D., Wallis, R., Milligan, P. A., and Jonsson, E. N. (2005). A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. *Clin. Pharmacol. Ther.* **77**(6):572-582.
- Kano, M., et al. (2005). QT PRODACT: Usability of miniature pigs in safety pharmacology studies: Assessment for drug-induced QT interval prolongation. *J. Pharmacol. Sci.* **99**: 501-511.
- Kiehn, J., Lacerda, A. E., and Brown, A. M. (1999). Pathways of HERG inactivation. *Am. J. Physiol.* **277**(1 Pt 2):H199-210.

- Kiehn, J., Lacerda, A. E., Wible, B., and Brown, A. M. (1996). Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. *Circulation*. **94**(10):2572-2579.
- Kijitawornrat, A., Sawangkoon, S., and Hamlin, R. L. (2012). Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts. *J. Toxicol. Sci.* **37**(3):455-462.
- Kirsch, G. E., Trepakova, E. S., Brimecombe, J. C., Sidach, S. S., Erickson, H. D., Kochan, M. C., Shyjka, L. M., Lacerda, A. E., and Brown, A. M. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. *J. Pharmacol. Toxicol. Methods*. **50**:93-101.
- Kodama, I., Kamiya, K., and Toyama, J. (1997). Cellular electropharmacology of amiodarone. *Cardiovascular Research*. **35**:13-29.
- Kraushaar, U., Meyer, T., Hess, D., Gepstein, L., Mummery, C. L., Braam, S. R., and Guenther, E. (2012). Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models. *Expert Opin. Drug Saf.* **11**:285-298.
- Kuryshv, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennia, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., Reynolds, W., and Rampe, D. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. *J. Pharmacol. Exp. Ther.* **312**(1):316-323.
- Laursen, M., et al. (2011). Characterization of cardiac repolarization in the Göttingen minipig. *J. Pharmacol. Toxicol. Methods*. **63**:186-195.
- Malik, M. (2004). Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. *J. Electrocardiol.* **37** (Suppl):25-33.
- Malik, M., Garnett, C. E., and Zhang, J. (2010). Thorough QT Studies: Questions and Quandaries. *Drug Saf.* **33**(1):1-14.
- Malik, M., Hnatkovam, K., Novotny, T., and Schmidt, G. (2008). Subject-specific profiles of QT/RR hysteresis. *Am. J. Physiol. Heart Circ. Physiol.* **295**(6):H2356-2363.
- Miyazaki, H., Watanabe, H., Kitayama, T., Nishida, M., Nishi, Y., Sekiya, K. et al. (2005). QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. *J. Pharmacol. Sci.* **99**: 523–529.
- Mittelstadt, S. W., and Hart, S. M. (2005). Effects of moxifloxacin on QT interval in conscious dogs. *J. Vet. Pharmacol. Ther.* **28**(3):253-256.
- Morganroth, J., Shah, R. R., and Scott, J. W. (2010). Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval). *Clin. Pharmacol. Ther.* **87**(2):166-174.
- Murakawa, Y., et al. (1992). Role of sympathovagal interaction in diurnal variation of QT interval. *Am. J. Cardiol.* **69**(4):339-343.
- Pollard, C. E., Abi-Gerges, N., Bridgland-Taylor, M. H., Easter, A., Harmer, A., Hammond, T. G., and Valentin, J. P. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. *Br. J. Pharmacol.* **159**: 12-21.
- Pond, A. L., et al. (2000). Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to functional I(kr) channels. *J. Biol. Chem.* **275**: 5997-6006.

- Rampe, D., and Brown, A. M. (2013). A history of the role of the hERG channel in cardiac risk assessment. *J. Pharmacol. Toxicol. Methods*. [Epub ahead of print].
- Roy, M., Dumaine, R., Brown, A. M. (1996). HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. *Circulation*. **94**(4):817-23.
- Soloviev, M. V., Hamlin, R. L., Barrett, R. M., Chengelis, C. P., and Schaefer, G. J. (2006). Different species require different QT corrections. *Cardiovascular Toxicology*. **6**(2):145-157.
- Spence, S., Soper, K., Hoe, C. M., and Coleman, J. (1998). The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance. *Toxicological Sciences*. **45**:247-258.
- Stockbridge, N., Zhang, J., Garnett, C., and Malik, M. (2012). Practice and challenges of thorough QT studies. *J. Electrocardiol.* **45**(6):582-587.
- Valentin, J. P., Pollard, C. E., Lainée, P., and Hammond, T. (2010). Value of nonclinical repolarization assays in supporting the discovery and development of safer medicines. *Br. J. Pharmacol.* **159**:25-33.
- Van de Water, A.; Verheyen, J., Xhonneux, R., and Reneman, R. S. (1989). An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. *J. Pharmacol. Toxicol. Methods*. **22**(3):207-217.
- Van der Linde, H. J., et al. (2008). The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. *Br. J. Pharmacol.* **154**:1474-1481.
- Vargas, H. M., Bass, A. S., Breidenbach, A., Feldman, H. S., Gintant, G. A., Harmer, A. R., Heath, B., Hoffmann, P., Lagrutta, A., Leishman, D., McMahon, N., Mittelstadt, S., Polonchuk, L., Pugsley, M. K., Salata, J. J., and Valentin, J. P. (2008). Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. *J. Pharmacol. Toxicol. Methods*. **52**:77-82.
- Webster, R., Leishman, D., and Walker, D. (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. *Curr. Opin. Drug Discov. Devel.* **5**(1):116-126.
- Weirich, J., and Antoni, H. (1998). Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. *Basic Research in Cardiology*. **93** (Suppl 1):125-132.
- Wible, B. A., Hawryluk, P., Ficker, E., Kuryshev, Y. A., Kirsch, G., and Brown, A. M. (2005). HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. *J. Pharmacol. Toxicol. Methods*. **52**(1):136-145.

Neurobehavioural assessment

- Arezzo, J. C., Litwak, M. S., and Zotova, E. G. (2011). Correlation and dissociation of electrophysiology and histopathology in the assessment of toxic neuropathy. *Toxicol Pathol.* **39**(1):46-51.
- Authier S, Delatte MS, Kallman MJ, Stevens J, Markgraf C. 2016. EEG in non-clinical drug safety assessments: current and emerging considerations. *J Pharmacol Toxicol Meth* (*In press and electronically available*).
- Castagné, V., Moser, P. C., and Porsolt, R. D. (2009). Preclinical behavioral models for predicting antipsychotic activity. *Adv. Pharmacol.* **57**:381-418.

- Gad, S. C., and Gad, S. E. (2003). A functional observational battery for use in canine toxicity studies: development and validation. *International Journal of Toxicology*. **22**:415-422.
- Gauvin, D. V., and Baird, T. J. (2008). A functional observational battery in non-human primates for regulatory-required neurobehavioral assessments. *J. Pharmacol. Toxicol. Methods*. **58**:88-93.
- Irwin, S. (1968). Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. *Psychopharmacologia*. **13**:222–257.
- Kallman MJ. (2015). Chapter 31. Central nervous system assessment in nonhuman primates: behavioral assessment, neurological (electroencephalography, nerve conduction), abuse liability, and cognitive assessment. In: *The nonhuman primate in nonclinical drug development and safety assessment* (Bluemel J, Korte S and Weinbauer GF editors). Amsterdam: Elsevier Press p 592-604.
- Karl, T., Pabst, R., and Von Hörsten, S. (2003). Behavioral phenotyping of mice in pharmacological and toxicological research. *Experimental & Toxicologic Pathology*. **55**:69-83.
- Mattson, J. L., Spencer, P. J., and Albee, R. R. (1996). A performance standard for clinical and functional observational battery examination of rats. *Journal of the American College of Toxicology*. **15**: 239-250.
- Moscardo, E., Fasdelli, N., Giarola, A., Tontodonati, M., and Dorigatti, R. (2009). An optimised neurobehavioural observation battery integrated with the assessment of cardiovascular function in the beagle dog. *J. Pharmacol. Toxicol. Methods*. **60**:198-209.
- Moscardo, E., McPhie, G., Fasdelli, N., Dorigatti, R., and Meecham, K. (2010). An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey. *J. Pharmacol. Toxicol. Methods*. **62**:95-106.
- Moser, V. C., Becking, G. C., MacPhail, R. C., and Kulig, B. M. (1997). The IPCS collaborative study on neurobehavioral screening methods. *Fundamental and Applied Toxicology*. **35**:143-151.
- Redfern, W. S., Strang, I., Storey, S., Heys, C., Barnard, C., Lawton, K., Hammond, T. G., and Valentin, J. P. (2005). Spectrum of effects detected in the rat Functional Observational Battery following oral administration of non-CNS targeted compounds. *J. Pharmacol. Toxicol. Methods*. **52**:77-82.
- Roux, S., Sablé, E., and Porsolt, R. D. (2005). Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. *Curr. Protoc. Pharmacol.* Chapter 10:Unit 10.10.
- Roux, S., Froger, C., Porsolt, R. D., Valverde, O., Maldonado, R. (2003). Place preference test in rodents. *Curr. Protoc. Neurosci.* Chapter 9:Unit 9.15.
- Tontodonati, M., Fasdelli, A., Moscardo, E., Giarola, A., and Dorigatti, R. (2007). A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs. *J. Pharmacol. Toxicol. Methods*. **56**:265-275.

Automated motor activity measurement

- Himmel, H. M. (2008). Safety pharmacology assessment of central nervous system function in juvenile and adult rats: Effects of pharmacological reference compounds. *J. Pharmacol. Toxicol. Methods.* **58**:129-146.
- Lynch, J. J., Castagné, V., Moser, P. C., and Mittelstadt, S. W. (2011). Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. *Journal J. Pharmacol. Toxicol. Methods.* **64**:74-80.
- Onishchenko, N., Fischer, C., Wan Ibrahim, W. N., Negri, S., Spulber, S., Cottic, D., and Ceccatelli, S. (2011). Prenatal exposure to PFOS or PFOA alters motor function in mice in a sex-related manner. *Neurotoxicity Research.* **19**:452-461.
- Patterson, J. P., Markgraf, C. G., Cirino, M., and Bass, A. (2005). Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds. *J. Pharmacol. Toxicol. Methods.* **52**:159-167.
- Rose, .C, De Heer, R. C., Horte, S., Van der Harst, J. E., Weinbauer, G. F., and Spruijt, B. M. (2012). Quantified tracking and monitoring of diazepam treated socially housed cynomolgus monkeys. *Regulatory Toxicology & Pharmacology.* **62**:292-301.
- Vinkers, C. H., Breuer, M. E., Westphal, K. G., Korte, S. M., Oosting, R. S., Olivier, B., and Groenink, L. (2009). Olfactory bulbectomy induces rapid and stable changes in basal and stress-induced locomotor activity, heart rate and body temperature responses in the home cage. *Neuroscience.* **159**:39-46.
- Vorhees, C. V., Acuff-Smith, K. D., Minck, D. R., and Butcher, R. E. (1992). A method for measuring locomotor behavior in rodents: contrast-sensitive computer-controlled video tracking activity assessment in rats. *Neurotoxicology & Teratology.* **14**:43-49.

CNS measurements (misc.)

- Authier, S., Paquette, D., Gauvin, D., Sammut, V., Fournier, S., Chaurand, F., and Troncy, E. (2009). Video-electroencephalography in conscious non human primate using radiotelemetry and computerized analysis: refinement of a safety pharmacology model. *J. Pharmacol. Toxicol. Methods.* **60**(1):88-93.
- Chapillon, P., Lalonde, R., Jones, N., and Caston, J. (1998). Early development of synchronised walking on the rotarod in rats – effects of training and handling. *Behav. Brain Res.* **93**:77-81.
- DeBoer, E. and Friedrichs, G. (2009). EEG telemetry models in the rodent and non-human primate. *J. Pharmacol. Toxicol. Methods.* **60**:217.
- Dürmüller, N., Guillaume, P., Lacroix, P., Porsolt, R. D., and Moser, P. (2007). The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk. *J. Pharmacol. Toxicol. Methods.* **56**(2):234-238.
- Fitch, R. H., Threlkeld, S. W., McClure, M. M., and Peiffer, A. M. (2008). Use of a modified prepulse inhibition paradigm to assess complex auditory discrimination in rodents. *Brain Research Bulletin.* **76**:1-7.

- Holliday, T. A., Nelson, H. J., Williams, D. C., and Willits, N. (1992). Unilateral and bilateral brainstem auditory-evoked response abnormalities in 900 Dalmatian dogs. *Journal of Veterinary Internal Medicine*. **6**:166-174.
- Horner, S. A., Gould, S., Noakes, J. P., Rattray, N. J., Allen, S. L., Zotova, E., and Arezzo, J. C. (2004). Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat. *Molecular Cancer Therapeutics*. **3**:783-791.
- Koch, M. (1999). The neurobiology of startle. *Progress in Neurobiology*. **59**:107-128.
- Krohn, T. C., Farlov, H., and Hansen, A. K. (2010). The effects of housing on food and water consumption in DA rats. *Scandinavian Journal of Laboratory Animal Science*. **37**:1-6.
- Porsolt, R. D. (2013). The usefulness of non-human primates in central nervous system safety pharmacology. *J. Pharmacol. Toxicol. Methods*. [Epub ahead of print].
- Porsolt, R. D., Lemaire, M., Durmuller, N., and Roux, S. (2002). New perspectives in CNS safety pharmacology. *Fundam. Clin. Pharmacol.* **16**:197-207. 1268.
- Porsolt, R. D., Niklaus, C. D., Lemaire, M., et al. (2006). *Central Nervous System (CNS) Safety Pharmacology Studies*. Springer, 1270, Germany.
- Porsolt, R. D. (2000). Animal models of depression: utility for transgenic research. *Rev Neurosci*. **11**(1):53-8.
- Rosolen, S. G., Rigaudiere, F., Le Gargasson, J. F., and Brigell, M. G. (2005). Recommendations for a toxicological screening ERG procedure in laboratory animals. *Documenta Ophthalmologica*. **110**:57-66.
- Redfern, W. S., Storey, S., Tse, K., Hussain, Q., Maung, K. P., Valentin, J. P., Ahmed, G., Bigley, A., Heathcote, D., and McKay, J. S. (2011). Evaluation of a convenient method of assessing rodent visual function in safety pharmacology studies: effects of sodium iodate on visual acuity and retinal morphology in albino and pigmented rats and mice. *J. Pharmacol. Toxicol. Methods*. **63**: 102-114.
- Stanley, J. L., Lincoln, R., Brown, T. A., McDonald, L. M., Dawson, G. R., Reynolds, D. S. (2005). The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. *Journal of Psychopharmacology*. **19**:221-227.
- Takeuchi, T., Kiyama, Y., Nakamura, K., Tsujita, M., Matsuda, I., Mori, H., Munemoto, Y., Kuriyama, H., Natsume, R., Sakimura, K., and Mishina, M. (2001). Roles of the glutamate receptor $\epsilon 2$ and $\delta 2$ subunits in the potentiation and prepulse inhibition of the acoustic startle reflex. *European Journal of Neuroscience*. **14**:153-160.

Drug Abuse

- Baird, T. J., and Gauvin, D. (2000). Characterization of cocaine self-administration and pharmacokinetics as a function of time of day in the rat. *Pharmacol. Biochem. Behav.* **65**(2):289-299.
- Gauvin DV, Zimmermann ZJ, Baird TJ. 2015. Preclinical assessment of abuse liability of biologics: in defense of current regulatory control policies. *Reg Toxicol Pharmacol* 73(1): 43-54.

Froger-Colléaux, C., Rompion, S., Guillaume, P., Porsolt, R. D., Castagné, V., and Moser, P. (2011). Continuous evaluation of drug withdrawal in the rat using telemetry: Effects of morphine and chlordiazepoxide. *J. Pharmacol. Toxicol. Methods.* **64**:81-88.

Horton, D. B., Potter, D. M., and Mead, A. N. (2013). A translational pharmacology approach to understanding the predictive value of abuse potential assessments. *Behav. Pharmacol.*

Moser, P., Wolinsky, T., Duxon, M., Porsolt, R. D. (2011). How good are current approaches to nonclinical evaluation of abuse and dependence? *J Pharmacol. Exp. Ther.* **336**(3):588-595.

Thermoregulation

Gordon, C. J. (1990). Thermal biology of the laboratory rat. *Physiology & Behaviour.* **47**:963-991.

Gordon, C. J., Spencer, P. J., Hotchkiss, J., Miller, D. B., Hinderliter, P. M., and Pauluhn, J. (2008) Thermoregulation and its influence on toxicity assessment. *Toxicology.* **244**: 87-97.

Gordon, C. J. (2010). Response of the thermoregulatory system to toxic insults. *Frontiers in Bioscience.* **2**:293-311.

Mattu, A., Brady, W. J., and Perron, A. D. (2002). Electrocardiographic manifestations of hypothermia. *Am. J. Emerg. Med.* **20**:314-326.

Rusyniak, D. E., and Sprague, J. E. (2005). Toxin-induced hyperthermic syndromes. *Medical Clinics of North America.* **89**:1277-1296.

Shellhammer, L. J., et al. (2009). Effects of Body Temperature on QT interval in beagle dogs. *J. Pharmacol. Toxicol. Methods.* **60**:237-238.

Swoap, S. J. (2008). The pharmacology and molecular mechanisms underlying temperature regulation and torpor. *Biochemical Pharmacology.* **76**:817-824.

Cardiovascular (general)

Authier, S., et al. (2007). A cardiovascular monitoring system in conscious cynomolgus monkeys for regulatory safety pharmacology. Part 1: Non-pharmacological validation. *J. Pharmacol. Toxicol. Methods.* **56**:115-121.

Authier, S., et al. (2007). A cardiovascular monitoring system used in conscious cynomolgus monkeys for regulatory safety pharmacology. Part 2: Pharmacological validation. *J. Pharmacol. Toxicol. Methods.* **56**:122-130.

Authier, S., et al. (2011). Cardiovascular and respiratory safety pharmacology in Göttingen minipigs: Pharmacological characterization. *J. Pharmacol. Toxicol. Methods.* **64**(1):53-9.

Baird, T. J., Bailie, M., Patrick, D. J., Moddrelle, D., Yoder J, Gauvin, D. V., and Dalton, J. A. (2013). Influence of surgically implantable telemetry solutions on in-life and post-mortem toxicology endpoints. *J. Pharmacol. Toxicol. Methods.* **67**(3):148-161.

Bass, A. S., Tomaselli, G., Bullingham, R. 3rd, and Kinter, L. B. (2005). Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. *J. Pharmacol. Toxicol. Methods.* **52**(1):12-21.

- Bilan, A., et al. (2005). Circadian rhythm of spectral indices of heart rate variability in healthy subjects. *J. Electrocardiol.* **38**(3):239-243.
- Chiang, A. Y., Smith, W. C., Main, B. W., and Sarazan, R. D. (2004). Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs. *J. Pharmacol. Toxicol. Methods.* **50**(2):121-130.
- Daneshvar, H., Edwards, T., Voss, K., Landis, K., Gleason, T., and Atterson, P. (2011). Cardiovascular assessment in radiotelemetry-implanted pregnant rats. *J. Invest. Surg.* **24**(1):35-43.
- Gauvin, D. V., Tilley, L. P., Smith, F. W. Jr., and Baird, T. J. (2006). Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry. *J. Pharmacol. Toxicol. Methods.* **53**(2):128-139.
- Gauvin, D. V., Tilley, L. P., Smith, F. W. Jr., and Baird, T. J. (2006). Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving cynomolgus monkey by remote radiotelemetry. *J. Pharmacol. Toxicol. Methods* **53**(2):140-151.
- Hassimoto, M., and Harada, T. (2003). Use of a telemetry system to examine recovery of the cardiovascular system after excitement induced by handling stress in a conscious cynomolgus monkey (*Macaca fascicularis*). *Journal of Medical Primatology* **32**:346-352.
- Hashimoto, M., et al. (1999). Diurnal variation of autonomic nervous activity in the rat - investigation by power spectral analysis of heart rate variability. *J Electrocardiol.* **32**(2): 167-171.
- Kinter, L. B. and Valentin, J. P. (2002). Safety pharmacology and risk assessment. *Fundam. Clin. Pharmacol.* **16**(3):175-182.
- Kinter, L. B., Siegl, P. K., and Bass, A. S. (2004). New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age. *J. Pharmacol. Toxicol. Methods.* **49**(3):153-158.
- Leishman, D. J., Beck, W., Dybdal, N., Gallacher, D. J., Guth, B. D., Holbrook, M., Roche, B., and Wallis, R. M. (2012). Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society. *J. Pharmacol. Toxicol. Methods.* **65**:93-101.
- McMahon, C., Mitchell, A. Z., Klein, J. L., Jenkins, A. C., and Sarazan, R. D. (2010). Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. *J. Pharmacol. Toxicol. Methods.* **62**:127-135.
- Pettit, S. D., Berridge, B., and Sarazan, R. D. (2010). A call for more integrated cardiovascular safety assessment. *J Pharmacol Toxicol Methods.* **61**(1):1-2.
- Sarazan, R. D., and Schweitz, K. T. (2009). Standing on the shoulders of giants: Dean Franklin and his remarkable contributions to physiological measurements in animals. *Adv. Physiol. Educ.* **33**(3):144-156.
- Sarazan, R. D., Mittelstadt, S., Guth, B., Koerner, J., Zhang, J., and Pettit, S. (2011). Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities. *Int. J. Toxicol.* **30**(3):272-286.
- Sarazan, R. D., Kroehle, J. P., and Main, B. W. (2012). Left ventricular pressure, contractility and dP/dt(max) in nonclinical drug safety assessment studies. *J. Pharmacol. Toxicol. Methods.* **66**(2):71-78.

Sato, K., Chatani, F., and Sato, S. (1995). Circadian and short-term variabilities in blood pressure and heart rate measured by telemetry in rabbits and rats. *J. Auton. Nerv. Syst.* **54**(3):235-246.

Cardiac injury/functional consequences

Authier, S., Pugsley, M.K., Troncy, E. and Curtis, M.J. (2010). Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies. *J. Pharmacol. Toxicol. Methods.* **62**(2):83-88.

Dogterom, P., Zbinden, G., and Reznik, G. K. (1992). Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. *Critical Reviews in Toxicology.* **22**:203-241.

Fridericia, L. S. (1920). The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. *Acta Med. Scandinavica.* **53**:469–486.

Greaves, P. (1998). Patterns of drug-induced cardiovascular pathology in the beagle dog: relevance for humans. *Experimental and Toxicologic Pathology.* **50**: 283–293.

Hamlin, R. L. (2007). Animal models of ventricular arrhythmias. *Pharmacol. Ther.* **113**: 276-295.

Hamlin, R.L., and Kijitawornratm A. (2008). Use of the rabbit with a failing heart to test for torsadogenicity. *Pharmacol Ther.* **119**(2):179-185.

Kijitawornrat, A., Panyasing, Y., Del Rio, C., and Hamlin, R. L. (2010). Assessment of ECG interval and restitution parameters in the canine model of short QT syndrome. *J. Pharmacol. Toxicol. Methods.* **61**(3):231-237.

Misner, D. L. Frantz, C. Guo, L. Gralinski, M. R., Senese, P. B., Ly, J., Albassam, M., and Kolaja, K. L. (2012). Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys. *Br. J. Pharmacol.* **165**:2771-2786.

Safety pharmacology reviews

Bass, A. S., Vargas, H. M., Kinter, L. B. (2004). Introduction to Nonclinical safety pharmacology and the safety pharmacology society. *J. Pharmacol. Toxicol. Methods.* **49**:141–144.

Bass, A. S., Vargas, H. M., Valentin, J. P., Kinter, L. B., Hammond, T., Wallis, R., Siegl, P. K., and Yamamoto, K. (2011). Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. *J. Pharmacol. Toxicol. Methods.* **64**(1):7-15.

Bass, A., Kinter, L., and Williams, P. (2004). Origins, practices and future of safety pharmacology. *J. Pharmacol. Toxicol. Methods.* **49**(3):145-151.

Ewart, L., Gallacher, D. J., Gintant, G., Guillon, J. M., Leishman, D., Levesque, P., McMahon, N., Mylecraine, L., Sanders, M., Suter, W., Wallis, R., and Valentin, J. P. (2012). How do the top 12 pharmaceutical companies operate safety pharmacology? *J. Pharmacol. Toxicol. Methods.* **66**(2):66-70.

- Ewart, L., Milne, A., Adkins, D., et al. (2013). A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions. *J. Pharmacol. Toxicol. Methods*. [Epub ahead of print].
- Hamdam, J., Sethu, S., Smith, T., et al. (2013). Safety pharmacology - Current and emerging concepts. *Toxicol. Appl. Pharmacol.* [Epub ahead of print].
- Pugsley MK, Authier S, Curtis MJ. 2013. Back to the future: safety pharmacology methods and models in 2013. *J Pharmacol Toxicol Meth* 68:1-6.
- Pugsley MK, Dalton JA, Authier S, Curtis MJ. 2014. Reprint of "Safety pharmacology in 2014: new focus on non-cardiac methods and models". *J Pharmacol Toxicol Meth* 70:199-203.
- Redfern, W. S., Wakefield, I. D., Prior, H., Pollard, C. E., Hammond, T. G., and Valentin, J. P. (2002). Safety pharmacology – a progressive approach. *Fund. Clin. Pharmacol.* **16**:161-173.
- Redfern, W. S., and Wakefield, I. D. (2006). Safety Pharmacology. In *Toxicological Testing Handbook: Principles, Applications and Data Interpretation* (K Keller & D Jacobson-Kram Eds.), 2nd ed., Taylor & Francis Ltd.
- Redfern, W. S., and Valentin, J. P. (2011). Trends in safety pharmacology: Posters presented at the annual meetings of the Safety Pharmacology Society 2001–2010. *J. Pharmacol. Toxicol. Methods.* **64**: 102-110.
- Porsolt, R. D., Lemaire, M., Dürkmüller, N., and Roux, S. (2002). New perspectives in CNS safety pharmacology. *Fundamental and Clinical Pharmacology.* **16**:197-207.
- Pugsley, M. K. (2004). Safety pharmacology matures into a unique pharmacological discipline. *J. Pharmacol. Toxicol. Methods.* **49**:137-139.
- Pugsley, M. K., Authier, S., Curtis, M. J. (2008). Principles of Safety Pharmacology. *Br. J. Pharmacol.* **154**(7):1382-1399.
- Pugsley, M. K., et al. (2010). Non-clinical models: validation, study design and statistical consideration in safety pharmacology. *J. Pharmacol. Toxicol. Methods.* **61**:1-3.
- Valentin, J. P., and Hammond, T. (2008). Safety and secondary pharmacology: successes, threats, challenges and opportunities. *J. Pharmacol. Toxicol. Methods.* **58**:77-87. 1310.
- Valentin, J. P., Bass, A. S., Atrakchi, A., Olejniczak, K., and Kannosuke, F. (2005). Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. *J. Pharmacol. Toxicol. Methods.* **52**:22-29.

ECG

- Bass, A. S., Hanson, L. A., and Jackson, T. A. (2009). Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures. *J. Pharmacol. Toxicol. Methods.* **60**:51-57.
- Bass, A. S., et al. (2005). Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. *J. Pharmacol. Toxicol. Methods.* **52**(1):12-21.
- Bazett, J. C. (1920). An analysis of time relations of electrocardiograms. *Heart.* **7**:353-367.

- Bexton, R. S., Vallin, H. O. and Camm, A. J. (1986). Diurnal variation of the QT interval-influence of the autonomic nervous system. *Br. Heart J.* **55**:253-258.
- Chui, R. W., Fosdick, A., Conner, R., Jiang, J., Bruenner, B. A., and Vargas, H. M. (2009). Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants. *J. Pharmacol. Toxicol Methods.* **60**:58-68.
- Cools, F., Janssens, S., Vanlommel, A., Teisman, A., Towart, R., and Gallacher, D. J. (2011). ECG arrhythmias in non-implanted vs. telemetry-implanted dogs: Need for screening before and sufficient recovery time after implantation. *J. Pharmacol. Toxicol Methods.* **64**:60-67.
- Cros, C., Skinner, M., Moors, J., Lainée, P., and Valentin, J. P. (2012). Detecting drug-induced prolongation of the QRS complex: New insights for cardiac safety assessment. *Toxicology and Applied Pharmacology.* **265**: 200-208.
- Detweiler, D. K. (1982). The use of electrocardiography in toxicological studies with beagle dogs. In: Balasz T, editor, *Cardiac Toxicology*, Boca Raton, Florida: CRC Press, pp. 33–82. **OR** Detweiler DK. (1997). *Electrocardiography in toxicological studies*. In: Snipes IG, McQueen CA, & Gandolfi AJ, (Eds) *Comprehensive Toxicology*. Pergamon Press, New York, USA. **OR** Detweiler, D.K. (1988). The mammalian electrocardiogram, in *Comprehensive Electrocardiography: Theory and Practice in Health and Disease* (MacFarlane, P.W. and Lawrie, T.D.V., Eds.). Pergamon, New York, NY.
- Gauvin, D. V., Tilley, L. P., Smith, F. W. Jr., Baird, T. J. (2009). Spontaneous cardiac arrhythmias recorded in three experimentally- and drug-naïve laboratory species (canine, primate, swine) during standard pre-study screening. *J. Pharmacol. Toxicol. Methods.* **59**(2):57-61.
- Hamlin, R. L. (2005). Non-drug-related electrocardiographic features in animal models in safety pharmacology. *J. Pharmacol. Toxicol. Methods.* **52**: 60-76.
- Hamlin, R. L. (2008). How many ECG leads are required for in vivo studies in safety pharmacology? *J. Pharmacol. Toxicol. Methods.* **57**(3):161-8.
- Hamlin, R. L. (2010). QRS in pigs versus in dogs. *J. Pharmacol. Toxicol. Methods.* **62**(1):4-5.
- Hammond, T. G., Carlsson, L., Davis, A. S., et al. (2001). Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. *Cardiovasc. Res.* **49**(4):741-750.
- Macallum, G. E., and Houston, B. J. (2009). Characterization of cardiac alterations in nonsedated cynomolgus monkeys. *Am. J. Vet. Res.* **54**:327-332.
- Nahas, K., Baneux, P., and Detweiler, D. (2002). Electrocardiographic monitoring in the Göttingen minipig. *Comparative Medicine.* **52**:258-264.
- Ohmura, T., Chachin, M., Tarui, S., Nagakura, A., Igarashi, T., Ikeda, H., Ikegami, K., Kitagawa, H., and Uchida, S. (1999). Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys. *European Journal of Pharmacology.* **378**:169-175.
- Prior, H., McMahon, N., Schofield, J., and Valentin, J. P. (2009). Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs. *J. Pharmacol. Toxicol Methods.* **60**:167-173.
- Stubhan, M., et al. (2008). Evaluation of cardiovascular and ECG parameters in the normal, freely moving Göttingen Minipig. *J. Pharmacol. Toxicol. Methods.* **57**:202-211.

Taylor, K., and Gleason, C. (2010). Effect of body position on limb lead electrocardiographic findings in sedated cynomolgus macaques (*Macaca fascicularis*). *Journal of the American Association for Laboratory Animal Science: JAALAS*. **49**:352-356.

Tilley, L. P. (1992). *Essentials of Canine and Feline Electrocardiography: Interpretation and Treatment*, 3rd ed., Lippincott Williams & Wilkins, Philadelphia, PA.

Ward, G., Milliken, P., Patel, B., and McMahon, N. (2012). Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs. *J. Pharmacol. Toxicol Methods*. **66**: 106-113.

Echocardiography

Hanton, G., Gautier, M., and Bonnet, P. (2004). Use of M-mode and Doppler echocardiography to investigate the cardiotoxicity of minoxidil in beagle dogs. *Archives of Toxicology*. **78**:40-48.

Hanton, G., Gautier, M., Bonnet, P., and Herbet, A. (2005). Effect of milrinone on echocardiographic parameters after single dose in Beagle dogs and relationship with drug-induced cardiotoxicity. *Toxicology Letters*. **155**:307-317.

Konrad, D., Weber, K., Corney, S., Allen, T. R., and Terrier, C. (2000). Echocardiography, color-coded Doppler imaging, and abdominal sonography, a non-invasive method for investigation of heart and aortic morphology and function in female gottingen minipigs: method and reference values for M-mode, B-mode, and flow parameters. *Comparative Medicine*. **50**:405-409.

Sleeper, M. M., Gaughan, J. M., Gleason, C. R., and Burkett, D. E. (2008). Echocardiographic reference ranges for sedated healthy cynomolgus monkeys (*Macaca fascicularis*). *Journal of the American Association for Laboratory Animal Science: JAALAS*. **47**:22-25.

Tsusaki, H., Yonamine, H., Tamai, A., Shimomoto, M., Iwao, H., Nagata, R., and Kito, G. (2005). Evaluation of cardiac function in primates using real-time three-dimensional echocardiography as applications to safety assessment. *J. Pharmacol. Toxicol. Methods*. **52**:182-187.

Non invasive blood pressure measurement

Feng, M., Whitesall, S., Zhang, Y., Beibel, M., D'Alecy, L., and DiPetrillo, K. (2008). Validation of volume-pressure recording tail-cuff blood pressure measurements. *American Journal of Hypertension*. **21**:1288-1291.

Haberman, C. E., Kang, C. W., Morgan, J. D., and Brown, S. A. (2006). Evaluation of oscillometric and Doppler ultrasonic methods of indirect blood pressure estimation in conscious dogs. *Canadian Journal of Veterinary Research*. **70**:211-217.

Kurtz, T. W., Griffin, K. A., Bidani, A. K., Davisson, R. L., and Hall, J. E. (2005). Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. *Hypertension*. **45**:299-310.

- McMahon, C., Mitchell, A. Z., Klein, J. L., Jenkins, A. C., and Sarazan, R. D. (2010). Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. *J. Pharmacol. Toxicol. Methods*. **62**(2):127-135.
- Meyer, O., Jenni, R., Greiter-Wilke, A., Breidenbach, A., and Holzgreffe, H. H. (2010). Comparison of telemetry and high-definition oscillometry for blood pressure measurements in conscious dogs: Effects of torcetrapib. *Journal of the American Association for Laboratory Animal Science*. **49**:464-471.
- Mitchell, A. Z., McMahon, C., Beck, T. W., and Sarazan, R. D. (2010). Sensitivity of two noninvasive blood pressure measurement techniques compared to telemetry in cynomolgus monkeys and beagle dogs. *J. Pharmacol. Toxicol. Methods*. **62**:54-63.
- Schmelting, B. (2009). Non-invasive blood pressure determination in *Macaca fascicularis* and *Callithrix jacchus* by high definition oscillometry. *J. Pharmacol. Toxicol. Methods*. **60**:234-235.
- Schmelting, B., Niehoff, M., Egner, B., Korte, S. H., and Weinbauer, G. F. (2009). High Definition Oscillometry: a novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (*Macaca fascicularis*). *J. Med. Primatol.* **38**:293-301.

Respiratory (incl. combined measurements)

- Authier, S., Legaspi, M., Gauvin, D., Chaurand, F., Fournier, S., and Troncy, E. (2009). Validation of respiratory safety pharmacology models: Conscious and anaesthetized beagle dogs. *J. Pharmacol. Toxicol. Methods*. **57**:52-60.
- Authier, S., Legaspi, M., Gauvin, D., and Troncy, E. (2009). Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys. *Regul. Toxicol. Pharmacol.* **55**(2):229-235.
- Authier, S., et al. (2010). Combined cardiopulmonary assessments with implantable telemetry device in conscious freely moving cynomolgus monkeys. *J. Pharmacol. Toxicol. Methods*. **62**(1):6-11.
- Ewart, L. C., Haley, M., Bickerton, S., Bright, J., Elliott, K., McCarthy, A., William, L., Ricketts, S. A., Holland, T., and Valentin, J. P. (2010). Pharmacological validation of a telemetric model for the measurement of bronchoconstriction in conscious rats. *J. Pharmacol. Toxicol. Methods*. **61**: 219-229.
- Harris, D., Graham, M., Price, J., Munro, F., Templeton, A., Young, R., Paterson, K., Anderson, L., Gillies, S., McKendrick, S., Low, G., Patmore, L., Bodine, R., Kallman, M. J., Hoffman, W. P., Lee C., and Wolff, R. K. (2005). Respiratory function in rats restrained for extended periods: Assessment of the effects of bethanecol. *J. Pharmacol. Toxicol. Methods*. **52**: 83-89.
- Hoymann, H. G. (2007). Invasive and noninvasive lung function measurements in rodents. *J. Pharmacol. Toxicol. Methods*. **55**:16-26.
- Kearney, K., Metea, M., Gleason, T., Edwards, T., and Atterson, P. (2010). Evaluation of respiratory function in freely moving Beagle dogs using implanted impedance technology. *J. Pharmacol. Toxicol. Methods*. **62**:119-126.
- Legaspi, M., Authier, S., Gauvin, D., Moreau, M., Beauchamp, G., Chaurand, F., and Troncy, E. (2010). Respiratory safety pharmacology: concurrent validation of volume, rate, time, flow and ratio variables in conscious male Sprague-Dawley rats. *Regul. Toxicol. Pharmacol.* **58**(3):444-450.

- Neumann, P., Zinserling, J., Haase, C., Sydow, M., Burchardi, H. (1998). Evaluation of respiratory inductive plethysmograph in controlled ventilation: Measurement of tidal volume and PEEP-induced changes of end-expiratory lung volume. *Chest*. **113**: 443-451.
- Murphy, D. J., Renninger, J. P., and Schramek, D. (2010). Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs. *J. Pharmacol. Toxicol. Methods*. **62**:47-53.
- Murphy, D. J. (2002). Assessment of respiratory function in safety pharmacology. *Fundamental and Clinical Pharmacology*. **16**:183-196.
- Murphy, D. J. (2005). Comprehensive non-clinical respiratory evaluation of promising new drugs. *Toxicol. Appl. Pharmacol.* **207**(Suppl 2):414-424.
- Murphy, D. J. (2003). Respiratory function assessment in safety pharmacology. *Curr. Protoc. Pharmacol.* Chapter 10:Unit10.9.
- Murphy, D. J., Renninger, J. P., and Coatney, R. W. (2001). A novel method for chronic measurement of respiratory function in the conscious monkey. *J. Pharmacol. Toxicol. Methods*. **46**(1):13-20.
- Murphy, D. J., Renninger, J. P., and Gossett, K. A. (1998). A novel method for chronic measurement of pleural pressure in conscious rats. *J. Pharmacol. Toxicol. Methods*. **39**(3):137-141.
- Raeburn, D., Underwood, S. L., and Villamil, M. E. (1992). Techniques for drug delivery to the airways, and the assessment of lung function in animal models. *J. Pharmacol. Toxicol. Methods*. **27**:143-159.
- Soloviev, M. V., Derchak, A., Setser, J. J., Steinbacher, E. A., Klemm, J. L., Gumpf, D. S., Shellhammer, L. J., Kearney, K. R., and Wilson, R. E. (2007). Concurrent cardiovascular and respiratory evaluation in conscious cynomolgus monkeys. *J. Pharmacol. Toxicol. Methods*. **56**:e30.

Gastrointestinal

- Akimoto, M., Nagahata, N., Furuya, A., Fukushima, K., Higuchi, S., and Suwa, T. (2000). Gastric pH profiles of beagle dogs and their use as an alternative to human testing. *European Journal of Pharmaceutics & Biopharmaceutics*. **49**:99-102.
- Boillat, C. S., Gaschen, F. P., and Hosgood, G. L. (2010). Assessment of the relationship between body weight and gastrointestinal transit times measured by use of a wireless motility capsule system in dogs. *American Journal of Veterinary Research*. **71**:898-902.
- Boillat, C. S., Gaschen, F. P., Gaschen, L., Stout, R. W., and Hosgood, G. L. (2010). Variability associated with repeated measurements of gastrointestinal tract motility in dogs obtained by use of a wireless motility capsule system and scintigraphy. *American Journal of Veterinary Research*. **71**:903-908.
- Chiu, P. J., Barnett, A., Tetzloff, G., and Kaminski, J. (1984). Gastric antisecretory properties of SCH 32651. *Archives Internationales de Pharmacodynamie et de Therapie*. **270**:116-127.
- Marona, H. R. N., and Lucchesi, M. B. B. (2004). Protocol to refine intestinal motility test in mice. *Laboratory Animals*. **38**:257-260.
- Martinez, M. N., and Papich, M. G. (2009). Factors influencing the gastric residence of dosage forms in dogs. *Journal of Pharmaceutical Sciences*. **98**:844-860.

Tsukamoto, A., Ohno, K., Tsukagoshi, T., Maeda, S., Nakashima, K., Fukushima, K., Fujino, Y., and Tsujimoto, H. (2011). Real-time ultrasonographic evaluation of canine gastric motility in the postprandial state. *Journal of Veterinary Medical Science*. **73**:1133-1138.

Sagawa, K., Li, F., Liese, R., and Sutton, S. C. (2009). Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. *Journal of Pharmaceutical Sciences*. **98**:2494-2500.

Sjödin, L., Visser, S., and Al-Saffar, A. (2011). Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs. *J. Pharmacol. Toxicol. Methods*. **64**:42-52.

Renal Function

Emeigh-Hart, S. G. (2005). Assessment of renal injury in vivo. *J. Pharmacol. Toxicol. Methods*. **52**(1):30-45.

Fuchs, T. C., and Hewitt, P. (2011). Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: what we know and what we need to know. *Biomark Med*. **5**(6):763-779.

Gabel, R. A., Ranaei, R. A., and Kivlighn, S. D. (1996). A new method of measuring renal function in conscious rats without the use of radioisotopes. *J. Pharmacol. Toxicol. Methods*. **36**:189-197.

Haas, M., Kluppel, A. C., Moolenaar, F., Meijer, D. K., De Jong, P. E., and De Zeeuw, D. (1997). Urine collection in the freely moving rat: reliability for measurement of short-term renal effects. *J. Pharmacol. Toxicol. Methods*. **38**:47-51.

Katayama, R., Yamaguchi, N., Yamashita, T., Watanabe, S., Satoh, H., Yamagishi, N., and Furuhashi, K. (2010). Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample. *J. Pharmacol. Toxicol. Methods*. **61**:59-64.

Laroute, V., Lefebvre, H. P., Costes, G., and Toutain, P. L. (1999). Measurement of glomerular filtration rate and effective renal plasma flow in the conscious beagle dog by single intravenous bolus of iohexol and p-aminohippuric acid. *J. Pharmacol. Toxicol. Methods*. **41**:17-25.

In vivo imaging

Brockmann, M. A., Kemmling, A., and Groden, C. (2007). Current issues and perspectives in small rodent magnetic resonance imaging using clinical MRI scanners. *Methods*. **43**:79-87.

Ghobadi, G., Van der Veen, S., Bartelds, B., De Boer, R. A., Dickinson, M. G., De Jong, J. R., Faber, H., Niemantsverdriet, M., Brandenburg, S., Berger, R. M., Langendijk, J. A., Coppes, R. P., and Van Luijk, P. (2012). Physiological interaction of heart and lung in thoracic irradiation. *International Journal of Radiation Oncology, Biology, Physics*. **84**:e639-646.

Melis, M., De Swart, J., De Visser, M., Berndsen, S. C., Koelewijn, S., Valkema, R., Boerman, O. C., Krenning, E. P., and De Jong, M. (2010). Dynamic and static small-animal SPECT in rats for monitoring renal function after ¹⁷⁷Lu-labeled Tyr3-octreotate radionuclide therapy. *J. Nucl. Med*. **51**:1962-1968.

Pollard, R. E., Dayton, P. A., Watson, K. D., Hu, X., Guracar, I.M., and Ferrara, K. W. (2009). Motion corrected cadence CPS ultrasound for quantifying response to vasoactive drugs in a rat kidney model. *Urology*. **74**:675-681.

Sadick, M., Attenberger, U., Kraenzlin, B., Kayed, H., Schoenberg, S. O., Gretz, N., and Schock-Kusch, D. (2011). Two non-invasive GFR-estimation methods in rat models of polycystic kidney disease: 3.0 Tesla dynamic contrast-enhanced MRI and optical imaging. *Nephrol. Dial. Transplant.* **26**:3101-3108.

Zhi, Z., Cepurna, W. O., Johnson, E. C., Morrison, J. C., and Wang, R. K. (2012). Impact of intraocular pressure on changes of blood flow in the retina, choroid, and optic nerve head in rats investigated by optical microangiography. *Biomedical Optics Express.* **3**: 2220-2233.

Biomarkers

Almy, F. S., Christopher, M. M., King, D. P., and Brown, S. A. (2002). Evaluation of cystatin C as an endogenous marker of glomerular filtration rate in dogs. *J. Vet. Intern. Med.* **16**:45-51.

Brott, D., Jones, H., Gould, S., Valentin, J. P., Evans, G., Richardson, R. J., and Loudon, C. (2005). Current status and future directions for diagnostic markers of drug-induced vascular injury. *Cancer Biomarkers.* **1**:15-28.

Hart, S. G. E. (2005). Assessment of renal injury in vivo. *J. Pharmacol. Toxicol. Methods.* **52**: 30-45.

Muller, P. Y., and Dieterle, F. (2009). Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. *Expert Opinion on Drug Metabolism & Toxicology.* **5**:1023-1038.

Schöttker, B., Herder, C., Müller, H., Brenner, H., and Rothenbacher, D. (2012). Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes. *Diabetes Care.* **35**:879-886.

Background information on toxicology studies

Baldrick, P. (2008). Safety evaluation to support first-in-man investigations II: Toxicology studies. *Regulatory Toxicology and Pharmacology.* **51**:237-243.

Bode, G., et al. (2010). The utility of the minipig as an animal model in regulatory toxicology. *J. Pharmacol. Toxicol. Methods.* **62**:196-220.

Bollen, P., and Ellegaard, L. (1997). The Göttingen minipig in pharmacology and toxicology. *Pharmacology and Toxicology.* **80**(Suppl 2):3-4.

Dorato, M. A., and Engelhart, J. A. (2005). The no-observed-adverse-effect-level in drug safety evaluations: Use, issues and definition(s). *Regulatory Toxicology and Pharmacology.* **42**:265-274.

Kramer, J. A., Sagartz, J. E., and Morris, D. L. (2007). The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. *Nat. Rev. Drug Discov.* **6**:636-649.

Lemmer, B. (1999). Chronopharmacokinetics: implications for drug treatment. *J. Pharm. Pharmacol.* **51**(8):887-890.

Muller, P. Y., and Milton, M. N. (2012). The determination and interpretation of the therapeutic index in drug development. *Nature Reviews Drug Discovery.* **11**: 751-761.